150 related articles for article (PubMed ID: 9477124)
1. Histamine and interleukin-2 in acute myelogenous leukemia.
Hellstrand K; Mellqvist UH; Wallhult E; Carneskog J; Kimby E; Celsing F; Brune M
Leuk Lymphoma; 1997 Nov; 27(5-6):429-38. PubMed ID: 9477124
[TBL] [Abstract][Full Text] [Related]
2. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia.
Brune M; Hellstrand K
Br J Haematol; 1996 Mar; 92(3):620-6. PubMed ID: 8616026
[TBL] [Abstract][Full Text] [Related]
3. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
Martner A; Rydström A; Riise RE; Aurelius J; Brune M; Foà R; Hellstrand K; Thorén FB
Oncotarget; 2015 Dec; 6(40):42569-74. PubMed ID: 26544512
[TBL] [Abstract][Full Text] [Related]
4. NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites.
Brune M; Hansson M; Mellqvist UH; Hermodsson S; Hellstrand K
Eur J Haematol; 1996 Oct; 57(4):312-9. PubMed ID: 8982295
[TBL] [Abstract][Full Text] [Related]
5. Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.
Thorén FB; Romero AI; Brune M; Hellstrand K
Expert Opin Biol Ther; 2009 Sep; 9(9):1217-23. PubMed ID: 19653866
[TBL] [Abstract][Full Text] [Related]
6. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML.
Romero AI; Thorén FB; Aurelius J; Askarieh G; Brune M; Hellstrand K
Scand J Immunol; 2009 Sep; 70(3):194-205. PubMed ID: 19703009
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.
Martner A; Thorén FB; Aurelius J; Söderholm J; Brune M; Hellstrand K
Expert Rev Hematol; 2010 Aug; 3(4):381-91. PubMed ID: 21083028
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission.
Cortes JE; Kantarjian HM; O'Brien S; Giles F; Keating MJ; Freireich EJ; Estey EH
Cancer; 1999 Apr; 85(7):1506-13. PubMed ID: 10193940
[TBL] [Abstract][Full Text] [Related]
9. Histamine and cytokine therapy.
Hellstrand K; Hermodsson S; Naredi P; Mellqvist UH; Brune M
Acta Oncol; 1998; 37(4):347-53. PubMed ID: 9743456
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia.
Rydström A; Hallner A; Aurelius J; Sander FE; Bernson E; Kiffin R; Thoren FB; Hellstrand K; Martner A
J Leukoc Biol; 2017 Aug; 102(2):467-474. PubMed ID: 28235771
[TBL] [Abstract][Full Text] [Related]
11. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Farag SS; George SL; Lee EJ; Baer M; Dodge RK; Becknell B; Fehniger TA; Silverman LR; Crawford J; Bloomfield CD; Larson RA; Schiffer CA; Caligiuri MA
Clin Cancer Res; 2002 Sep; 8(9):2812-9. PubMed ID: 12231521
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
[TBL] [Abstract][Full Text] [Related]
13. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial.
Brune M; Castaigne S; Catalano J; Gehlsen K; Ho AD; Hofmann WK; Hogge DE; Nilsson B; Or R; Romero AI; Rowe JM; Simonsson B; Spearing R; Stadtmauer EA; Szer J; Wallhult E; Hellstrand K
Blood; 2006 Jul; 108(1):88-96. PubMed ID: 16556892
[TBL] [Abstract][Full Text] [Related]
14. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
15. Histamine dihydrochloride: in the management of acute myeloid leukaemia.
Yang LP; Perry CM
Drugs; 2011 Jan; 71(1):109-22. PubMed ID: 21175244
[TBL] [Abstract][Full Text] [Related]
16. Spotlight on histamine dihydrochloride in acute myeloid leukaemia.
Yang LP; Perry CM
Drugs Aging; 2011 Apr; 28(4):325-9. PubMed ID: 21428467
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with allogeneic neuraminidase-treated blasts for maintenance in acute myelogenous leukemia (AML). Significant prolongation of remission duration in patients receiving at least 3 cycles of therapy.
Urbanitz D; Pielken HJ; Koch P; Büchner T; Hiddemann W; Heinecke A; Wendt F; Maschmeier G; van de Loo J
Onkologie; 1985 Jun; 8(3):157-9. PubMed ID: 3895098
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 therapy in relapsed acute myelogenous leukemia.
Meloni G; Vignetti M; Pogliani E; Invernizzi R; Allione B; Mirto S; Sica S; Leoni F; Selleri C; Mandelli F
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S43-7. PubMed ID: 9457393
[TBL] [Abstract][Full Text] [Related]
19. Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: a report from the Children's Cancer Group.
Sievers EL; Lange BJ; Sondel PM; Krailo MD; Gan J; Liu-Mares W; Feig SA
J Clin Oncol; 1998 Mar; 16(3):914-9. PubMed ID: 9508173
[TBL] [Abstract][Full Text] [Related]
20. Histamine in cancer immunotherapy.
Hellstrand K; Hermodsson S; Brune M; Naredi P; Carneskog J; Mellqvist UH
Scand J Clin Lab Invest; 1997 May; 57(3):193-202. PubMed ID: 9238754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]